Cancer has quietly become the pharmaceutical industry’s most lucrative disease area. In 2024 alone, global cancer drug sales exceeded $200 billion, making oncology the single largest revenue category in biopharma, well ahead of even the fast-growing obesity drug market. Yet behind the blockbuster numbers and steady stream of approvals, a more troubling reality is emerging. Many of today’s most profitable cancer drugs do not meaningfully extend patients’ lives.
A recent Bloomberg investigation underscored the scale of the disconnect. Reviewing 176 cancer drugs approved since 2000, Bloomberg found that fewer than half have ever demonstrated a clear improvement in overall survival. Prices, however, have continued to climb. The median monthly cost of newly approved cancer drugs now exceeds $25,000, regardless of whether patients live longer or feel better.
The widening gap between cost, clinical benefit, and patient outcomes is prompting a broader reckoning in oncology. It is also creating an opening for a new generation of precision therapies that aim to rethink how cancer is treated, rather than layering incremental changes onto existing approaches.
The plateau of immunotherapy
To understand the current moment, it helps to revisit the immunotherapy revolution that began in 2011. Immune checkpoint inhibitors were a genuine breakthrough, enabling the immune system to recognize and attack cancer in ways that were previously impossible. For diseases such as metastatic melanoma, where survival prospects were once bleak, these therapies delivered unprecedented responses.
More than a decade later, however, the gains have flattened.
“Market-driven cancer drug development has largely been uninspired in recent years,” said Dr. Carman Giacomantonio, chief medical officer of Canadian oncology treatment developer Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF). “The truly remarkable response rates witnessed with checkpoint-focused immunotherapies have plateaued.”
Even in melanoma, one of the most immunogenic cancers, single-agent checkpoint inhibitors produce objective response rates of roughly 33 to 42 percent. Five-year survival tops out around 41 percent, while complete responses occur in only 15 to 20 percent of patients. The majority eventually relapse.
To push response rates higher, companies turned to combination regimens that pair two or more checkpoint inhibitors. While these combinations can raise response rates toward 60 percent, they come with a steep tradeoff. Severe toxicity rates can rise to 50 percent or more, significantly affecting quality of life.
When progression is not survival
Bloomberg’s reporting also highlighted how the oncology market continued to grow despite these limitations. A major factor has been regulatory change. Over the past three decades, the US Food and Drug Administration increasingly relied on surrogate endpoints, particularly progression-free survival, to speed cancer drugs to market.
Progression-free survival measures whether tumor growth slows over a short period of time. While it can provide early signals of activity, it does not necessarily mean patients live longer or live better. Multiple studies have shown that improvements in progression-free survival often fail to translate into gains in overall survival.
From 1999 to 2015, nearly two-thirds of trials aimed at slowing tumor progression were deemed successful. Long-term follow-up later revealed that only 38 percent of those drugs actually improved survival, according to Bloomberg.
Once approved, many of these therapies became commercial blockbusters. Insurers are effectively required to cover cancer drugs, giving manufacturers broad pricing power. Early approval can also create durable market advantages, even if later data fails to confirm a survival benefit.
The result, as Bloomberg described it, is a system that rewards speed and volume, while patients absorb the cost, uncertainty, and toxicity.
Patent cliffs and a broken incentive system
Another pressure point is now approaching. Over the next two years, many of the world’s leading checkpoint inhibitors are set to lose patent protection.
“Once off patent, there is little financial incentive for companies to continue investing heavily in further development,” Giacomantonio said. “That’s a fundamental flaw in the system.”
Immunotherapy is reaching its scientific limits just as its economic engine begins to slow. For large drugmakers, extracting incremental benefit from aging assets is becoming harder. For patients, the proliferation of new drugs does not necessarily translate into better outcomes.
This convergence is forcing a long-avoided question: what should success in cancer treatment actually mean?
Making tumors visible to the immune system
For emerging precision oncology companies like Sona Nanotech, the answer starts with a different premise.
All cancers contain potentially targetable antigens, Giacomantonio explained, but the challenge is that many tumors are effectively invisible to the immune system. Sona’s targeted hyperthermia therapy aims to change that. Instead of exposing the entire body to systemic drugs, the therapy applies precisely controlled heat within the tumor microenvironment. This localized treatment alters cancer cells in a way that releases large quantities of tumor antigens, making the cancer more recognizable to the immune system. Essentially, the tumor becomes its own vaccine.
Because the therapy is localized, systemic exposure and toxicity are minimized. The immune response generated at the tumor site then spreads throughout the body, similar to how immunity from a traditional vaccine becomes systemic.
A different definition of success
Sona recently completed a first-in-human study involving 10 melanoma patients who had failed all standard treatments. In that proof-of-concept trial, eight patients responded to therapy, with six demonstrating complete pathological responses in representative tumors just two weeks after treatment began. No patient experienced toxicity beyond grade one.
Early data always warrants caution. Still, in a field where success has often been defined by modest delays in tumor progression, the signal Sona is emphasizing is different. Rapid tumor response paired with minimal side effects.
“At the risk of overstating, we believe this is the correct path forward,” Giacomantonio said. “Success means achieving maximum tumor response with minimum treatment-related toxicity. Accepting the premise that all cancers contain critically important antigens, and that proper presentation of these antigens to the immune system is the key to stronger immunity, Sona’s THT treatment protocols will lead the way to changing how we, and others, treat cancers going forward.”
After two decades of spending billions to extract smaller gains, oncology may finally be ready for a reset.